Back to results
US 10,238,658 B2Granted
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
AssigneeRespivert Limited
InventorsKazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
Life of this patent
Estimating the term…
Abstract
There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
Claims19
A dry powder pharmaceutical formulation for inhalation comprising:
- (i) a compound of formula (I)
- wherein:
- R1 represents C1-10 alkyl, C3-10 cycloalkyl or halo substituted C1-10 alkyl,
- R2 represents hydrogen, hydroxyl, halogen, C1-6 alkyl or C1-6 alkoxy,
- R3 represents phenyl optionally substituted by 1 to 3 substituents independently selected from hydroxyl, halogen, C1-6 alkyl, and C1-6 alkoxy,
- or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof;
- and
- (ii) an excipient.
5 more elements
Dependencies are inferred from the claim text.